Dogra J, Aneja N, Lal B B, Mishra S N
Department of Medicine and Dermatology, S.P. Medical College, Bikaner, India.
Int J Dermatol. 1990 Nov;29(9):661-2. doi: 10.1111/j.1365-4362.1990.tb02593.x.
Fifteen patients with cutaneous leishmaniasis were randomly selected for clinical trials with itraconazole. A single daily itraconazole dose of approximately 4 mg per 1 kg of body weight was administered to each patient with breakfast for 6 weeks. Five patients served as controls. On completion of therapy, ten cases in the study group (66.6%) were considered to be cured. No major adverse effects were reported. No significant changes were seen in the controls at the end of the study. The possibility of spontaneous recovery will be discussed in this report even though it is considered to be unlikely. Itraconazole has promising potential in cutaneous leishmaniasis therapy.
随机选择15例皮肤利什曼病患者进行伊曲康唑临床试验。每位患者每天早餐时服用约每1千克体重4毫克的伊曲康唑，持续6周。5名患者作为对照。治疗结束时，研究组中有10例（66.6%）被认为治愈。未报告重大不良反应。研究结束时，对照组未见明显变化。尽管认为自发恢复的可能性不大，但本报告仍将对此进行讨论。伊曲康唑在皮肤利什曼病治疗中具有广阔的潜力。
